I always said Alectinib is inferior to Brigatinib. Additional proof today: "Alectinib patients can die after suffering the G1202r mutation but Brigatinib patients DO NOT SUFFER RELAPSE as Alectininb patients DO from this mutation. In addition, Alectinib patients are sick as dogs from that drug. Brigatinib patients tolerate the drug very well and enjoy a good quality of life. Therefore those here who compate Alectinib to Brigatinib are simply WRONG!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.